Walleye Capital LLC Buys New Position in TriSalus Life Sciences, Inc. (NASDAQ:TLSI)

Walleye Capital LLC bought a new stake in shares of TriSalus Life Sciences, Inc. (NASDAQ:TLSI) in the third quarter, HoldingsChannel.com reports. The institutional investor bought 14,376 shares of the company’s stock, valued at approximately $66,000.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the business. Wolverine Asset Management LLC bought a new position in shares of TriSalus Life Sciences during the second quarter valued at approximately $240,000. Duquesne Family Office LLC raised its holdings in TriSalus Life Sciences by 35.1% in the second quarter. Duquesne Family Office LLC now owns 426,921 shares of the company’s stock worth $2,357,000 after purchasing an additional 110,966 shares in the last quarter. Finally, Highbridge Capital Management LLC bought a new position in TriSalus Life Sciences in the second quarter worth $1,184,000. Institutional investors own 2.58% of the company’s stock.

TriSalus Life Sciences Price Performance

Shares of NASDAQ:TLSI opened at $3.97 on Friday. TriSalus Life Sciences, Inc. has a 1-year low of $3.50 and a 1-year high of $10.42. The company has a market capitalization of $121.06 million, a PE ratio of -1.55 and a beta of 0.55. The business has a fifty day moving average price of $4.21 and a 200-day moving average price of $5.10.

Analyst Upgrades and Downgrades

A number of research firms have issued reports on TLSI. Roth Capital upgraded TriSalus Life Sciences to a “strong-buy” rating in a report on Monday, November 11th. Northland Securities began coverage on TriSalus Life Sciences in a report on Friday, October 25th. They issued an “outperform” rating and a $12.50 price objective for the company. Oppenheimer began coverage on TriSalus Life Sciences in a report on Monday, September 16th. They issued an “outperform” rating and a $10.00 price objective for the company. Roth Mkm assumed coverage on TriSalus Life Sciences in a report on Monday, November 11th. They issued a “buy” rating and a $11.00 price objective for the company. Finally, Northland Capmk upgraded TriSalus Life Sciences to a “strong-buy” rating in a report on Friday, October 25th. Six research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat.com, TriSalus Life Sciences presently has a consensus rating of “Buy” and a consensus price target of $12.08.

TriSalus Life Sciences Profile

TriSalus Life Sciences, Inc, a medical technology company, researches, develops, and sells drug delivery technologies and immune-oncology therapeutics for the treatment of liver and pancreatic cancer. The company offers Pressure Enabled Drug Delivery infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial, for locally advanced pancreatic cancer.